AccuPulse

AccuPulse Medical Technology (Suzhou) Co., Ltd. was founded in November 2020 and is committed to becoming an internationally leading platform-based innovative technology company in the field of cardiac electrophysiology. The core team comes from multinational corporations such as Johnson & Johnson, GE, Acutus Medical, and Abbott, with extensive experience in the research, development, registration, and commercialization of cardiac electrophysiology medical devices. Since its establishment, the company has formed a research and development team led by well-known electrophysiology technology experts from the United States and has received strong support from overseas returnee scientists, renowned clinical experts, and venture capital institutions. The company has R&D centers in both Suzhou, China, and the United States. AccuPulse independently develops pulsed field ablation (PFA) technology, using atrial fibrillation ablation as the entry point, and is taking the lead in developing a host device and ablation catheters while further expanding into a three-dimensional mapping and navigation system and new supporting tools. In the future, the company will also extend its focus to tumor ablation therapy, creating an integrated solution for the development of active pulse ablation devices and associated consumables for both atrial fibrillation and tumors.